Horizon Two: HR NDMM (MMRC-100)

June 8, 2026 updated by: Multiple Myeloma Research Consortium

MMRC Horizon Two: A Phase II Randomized Adaptive Platform Trial Integrating Novel Therapies in High-Risk-Newly Diagnosed Multiple Myeloma (MMRC-100)

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The master protocol has broad scope and substantial flexibility, allowing each investigational arm within the platform to have its own design. The master protocol specifies general principles but the analysis plan for each investigational arm will be specified in its appendix. Details outlined in each investigational arm's appendix will include any co-primary endpoints (if applicable), the comparator arm, sample size and justification, inclusion of a safety run-in (if required), and any potential adaptations within the appendix. Accrual to an investigational arm will terminate in accord with its appendix.

As an adaptive platform trial, MMRC Horizon Two will evaluate multiple investigational arms against common controls. It is expected that the common controls may vary over time as standard of care therapy evolves. An initial common control arm will be specified in the control arm appendix. Changes in the common controls will be made through amendments to this appendix.

All patients will be randomized to an arm in the study. The default for the platform will be equal randomization to all arms that a patient is eligible. However, when there are more than two investigational arms and response adaptive randomization is deemed beneficial, it may be implemented in the trial.

Participants will be on study for 5 years from the date of randomization, inclusive of treatment and follow-up periods. Specifics on treatment duration and duration of follow up will be included in the respective arm appendix.

Study Type

Interventional

Enrollment (Estimated)

300

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Georgia
      • Atlanta, Georgia, United States, 30017
    • Illinois
      • Chicago, Illinois, United States, 60637
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Recruiting
        • Karmanos Cancer Institute
        • Contact:
    • Minnesota
      • Rochester, Minnesota, United States, 55902
    • Missouri
      • St Louis, Missouri, United States, 63130
        • Recruiting
        • Washington University Medical Center
        • Contact:
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center
        • Contact:
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Voluntarily agree to participate by giving written informed consent

    -≥18 years of age

  • Symptomatic and transplant eligible newly diagnosed multiple myeloma histologically confirmed per IMWG criteria that is high-risk as defined by at least one of the following:

    • Del(17p) (CCF ≥ 20%, by analyses conducted on CD138-positive/purified cells) and/or TP53 mutation assessed by NGS
    • One of these translocations-t(4;14) or t(14;16) or t(14;20)-co-occurring with +1q and/or del(1p32)
    • Monoallelic del(1p32) along with +1q, or biallelic del(1p32)
    • High β2M (≥5.5 mg/dL) with normal creatinine (<1.2 mg/dL)
    • Presence of extra-medullary disease non-contiguous with bone at diagnosis (by PET-CT or Whole Body MRI)
    • Primary plasma cell leukemia (circulating plasma cells > 5% at diagnosis)
  • No more than 2 cycles of NCCN listed induction therapy for multiple myeloma

  • Measurable disease, per IMWG criteria, at time of diagnosis defined as one of the following:

    • Serum M-protein at diagnosis ≥ 0.5g/dL (0.3 g/dL or above if IgA subtype)
    • Urine M-protein ≥ 200 mg/24hours
    • Serum free light chain difference > 100 mg/L
    • Plasmacytoma ≥ 2cm
    • Bone marrow involvement ≥ 30%
  • ECOG performance status of 0-2

  • Adequate organ function, as indicated by the following laboratory values:

    • Adequate hematological function, defined as ANC ≥ 1000/µL, platelet count ≥ 75,000/µL, and hemoglobin ≥ 8 g/dL (transfusion and/or growth factor support is allowed for hematologic parameters as long as the investigator deems the patient otherwise fit for screening)
    • Adequate hepatic function, defined as total bilirubin level ≤ 1.5 x institutional upper limit of normal (IULN) except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin ≤1.5 x IULN is required), AST ≤ 2.5 x IULN, and ALT ≤ 2.5 x IULN
    • Adequate renal function, defined as calculated creatinine clearance ≥ 30 mL/min per institutional standard (assessment method should be recorded, measured or C-G acceptable)

  • Persons of childbearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of trial medication). Non-childbearing potential for a person assigned as female at birth is defined as 1 of the following:

    --≥ 45 years of age and has not had menses for >1 year

    • Amenorrheic for > 2 years without a hysterectomy and/or oophorectomy and follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation
    • Status is post-hysterectomy, -oophorectomy, or -tubal ligation

  • Persons of childbearing potential must be willing to use highly effective contraceptive measures during sexual contact with a person assigned as male at birth starting with the Screening visit through 90 days after last dose of trial medication.

    --Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.

  • Persons assigned as male at birth with a partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial starting with the Screening visit through 90 days after the last dose of trial medication is received. Persons assigned as male at birth with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

    --Note: Abstinence is acceptable if this is the established and preferred contraception method for the participant.

  • Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using New York Heart Association Functional Classification. To be eligible for this trial, participants should be Class 2 or better. Class 2 is defined as slight limitation of physical activity, in which ordinary physical activity leads to fatigue, palpitation, or dyspnea; the person is comfortable at rest.
  • Prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of the investigational arms are eligible for this trial.
  • Known HIV infection and on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated.
  • History of hepatitis C virus (HCV) infection must have been treated and cured. For patients with known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

  • Major concurrent illness or organ dysfunction including but not limited to the following:

    • POEMS syndrome
    • Symptomatic major organ involvement AL amyloidosis
  • History of allergy or known hypersensitivity to any of the trial therapies or any of their excipients, or contraindication to any of the trial therapies as outlined in the local prescribing information (e.g., United States Prescribing Information [USPI])
  • Complete spinal cord compression or CNS involvement
  • Known leptomeningeal disease
  • Allogeneic tissue/solid organ transplant recipients with chronic GVHD requiring steroid equivalent dose of > 20 mg prednisone
  • Active infection requiring treatment
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
  • Psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
  • Legally incapacitated or has limited legal capacity
  • Persons who are pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control Arm: Isa-KRd with Autologous Stem Cell Transplant
Appendix A to the MMRC Horizon Two High Risk Newly Diagnosed Multiple Myeloma Master Protocol: Isa-KRd with Autologous Stem Cell Transplant in Patients with High Risk Newly Diagnosed Multiple Myeloma
Drug: Monoclonal Antibody with Stem Cell Transplant
Isatuximab-KRd with Autologous Stem Cell Transplant
Other Names:
  • Isatuximab
Experimental: Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy
Appendix B to the MMRC Horizon Two High Risk Newly Diagnosed Multiple Myeloma Master Protocol: Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy in Patients with High Risk Newly Diagnosed Multiple Myeloma
Drug: Bispecific Monoclonal Antibody and Triplet Therapy
Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy
Other Names:
  • Linvoseltamab

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sustained measurable residual disease (MRD) negativity
Time Frame: 2 years post randomization
Sustained MRD negativity is defined as MRD negativity at a minimum threshold of one myeloma cell in one hundred thousand nucleated bone marrow cells at MRD assessments
2 years post randomization
Progression Free Survival
Time Frame: through study completion, roughly 5 years
PFS is defined as time from randomization to disease progression or death from any cause. Participants who have not progressed or died are censored at the date last known progression-free.
through study completion, roughly 5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR)
Time Frame: 2 years
ORR is defined as the percentage of people who have achieved a partial response (PR) or better according to the IMWG criteria within the defined period of time on trial.
2 years
Best overall response
Time Frame: 2 years
Best overall response (Stringent Complete Response [sCR], Complete Response [CR], Very Good Partial Response [VGPR], Partial Response [PR], Stable Disease [SD], Progressive Disease [PD]) by International Myeloma Working Group Response Criteria.
2 years
Two-year progression free survival rate
Time Frame: 24 months after randomization
Two-year progression free survival rate is defined as the proportion of participants alive and progression-free 24 months after randomization.
24 months after randomization
Overall survival (OS)
Time Frame: through study completion, average of 5 years
OS is defined as the time from randomization to death. Alive participants are censored at the date last known alive.
through study completion, average of 5 years
Duration of response (DoR)
Time Frame: 2 years
DoR is defined as time from the first observation of a confirmed response [Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR)] to first documentation of disease progression or death. Participants who have not progressed or died are censored at the date last known progression-free. The start date for DoR is the date the response was first observed, not the date of confirmation.
2 years
12-month measurable residual disease (MRD) negativity
Time Frame: 12 months from randomization
12-month MRD negativity is defined as MRD negativity at a minimum threshold of one myeloma cell in one hundred thousand nucleated bone marrow cells at MRD assessment at disease restaging 1 (12 months±3 months from randomization). Measured using ClonoSEQ's standardized, commercial, next generation sequencing assay (preferred) or commercial multi-color flow cytometry.
12 months from randomization
Frequency and intensity of (serious) adverse events (S)AEs
Time Frame: through study completion, an average of 5 years
Assessed by NCI CTCAE version 5.0, including a focus on hematologic clinical laboratory abnormalities and changes.
through study completion, an average of 5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Multiple Myeloma Research Consortium

Investigators

  • Principal Investigator: Hearn Jay Cho, MD, PhD, Multiple Myeloma Research Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 30, 2026

Primary Completion (Estimated)

October 1, 2035

Study Completion (Estimated)

October 12, 2035

Study Registration Dates

First Submitted

May 28, 2025

First Submitted That Met QC Criteria

June 26, 2025

First Posted (Actual)

July 8, 2025

Study Record Updates

Last Update Posted (Actual)

June 10, 2026

Last Update Submitted That Met QC Criteria

June 8, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MMRC-100

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on High Risk Newly Diagnosed Multiple Myeloma

Clinical Trials on Monoclonal Antibody with Stem Cell Transplant

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe